Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.284 SEK | -1.90% | -9.84% | -30.31% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.66M | Sales 2022 | 3.04M 280K | Capitalization | 234M 21.49M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.24M | Net income 2022 | -357M -32.86M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 7.99M | Net cash position 2022 | 134M 12.36M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 week | -8.10% | ||
Current month | -6.76% | ||
1 month | -11.47% | ||
3 months | -14.09% | ||
6 months | +35.28% | ||
Current year | -28.96% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.284 | -1.90% | 318 865 |
24-04-25 | 0.2895 | -0.86% | 714,025 |
24-04-24 | 0.292 | -4.89% | 653,642 |
24-04-23 | 0.307 | -0.32% | 260,389 |
24-04-22 | 0.308 | -2.22% | 679,297 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:42 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.96% | 14.28M | |
+24.85% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.14% | 233B | |
+5.53% | 201B | |
-9.98% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- VIVE Stock